These innovative compounds represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose https://joshaxrn919815.answerblogs.com/39505074/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide